Csl Behring Gmbh

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Ingo Pragst

Gerhard Dickneite

Matthias Grauert

Christoph Hoenke

Matthias Hoffmann

Alexander Pautsch

Michael Paul Pieper

Stefan Scheuerer

Steffen Breitfelder

Trixi Brandl

Udo Maier

Klaus Erb

Anne T Joergensen

Stefan Zeitler

Stefan Schulte

Marc Nolte

Henrique Lessa

Thorsten Haas

Bernhard Nieswandt

Christoph Kleinschnitz

Guido Stoll

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces

The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

Use of C1-inhibitor for the treatment of secondary edema of the central nervous system

The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.

von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

The present invention relates to compounds of general formula (I), wherein the groups A, R, R, Rand Rhave the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Thiazolyl-dihydro-quinazolines

Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups Rto Rhave the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Thiazolyl-dihydro-quinazoline compounds and processes for preparing same

Thiazolyl-dihydro-quinazoline

Disclosed are compounds of general formula (I), wherein the groups R, R, Rand Rhave the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Thiazolyl-dihydro-cyclopentapyrazole

Growing community of inventors

Marburg, Germany

Ingo Pragst